Pharmascience Canada Methotrexate Launch Package MARCH 2016

Pharmascience Canada Methotrexate Launch Package MARCH 2016

Pharmascience proudly announces the distribution of PrMETHOTREXATE, now available for shipping across Canada.

PrMETHOTREXATE is a registered trademark of Wyeth, licensee Pfizer Canada Inc.

Catalogue Number: 6606381810
UPC : 0 6606381810 5
DIN : 02170698
Product Description : PrMETHOTREXATE
Format : 100 tabs

The CAPP classification for this product is D.

Please note that PrMETHOTREXATE will be covered in our Fee for Service Agreement in all provinces excluding Quebec and Saskatchewan.

For additional information please refer to the following pages. Should you require further details, please contact me at 1-800-363-8805.

Best Regards,
Danielle Chouinard

Product Information

Indication:

Two major fields of indication exist for methotrexate:
• Neoplastic diseases
• Disease Modifying Antirheumatic Drug

Therapeutic Classification: Antimetabolite

Sales Execution

Pricing Strategy: Both competitors are at the same price, $0.6325 per tablet

Competition: Teva has the ultra-generic but the contract has been discontinued. Hospira is distributed by Apotex at a retail level. After Teva runs out of stock, this will be a dual source molecule.

Shelf Life: 36 months

Customer Service: 1-800-340-9735

Medical Information: 1-888-463-6001

The product monograph is available through our medical department.

Call 1-888-463-6001 or visit www.pfizer.ca.